Cargando…
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
BACKGROUND: Secukinumab treatment has previously been shown to significantly improve the signs and symptoms of active ankylosing spondylitis (AS), with responses sustained through 2 years. Here, we report the long-term (3 years) efficacy and safety of secukinumab in the MEASURE 2 study. METHODS: MEA...
Autores principales: | Marzo-Ortega, Helena, Sieper, Joachim, Kivitz, Alan, Blanco, Ricardo, Cohen, Martin, Delicha, Evie-Maria, Rohrer, Susanne, Richards, Hanno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761290/ https://www.ncbi.nlm.nih.gov/pubmed/29435364 http://dx.doi.org/10.1136/rmdopen-2017-000592 |
Ejemplares similares
-
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
por: Marzo‐Ortega, H., et al.
Publicado: (2017) -
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019) -
Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016) -
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018) -
Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)